# OnCo record transcend (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/transcend/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "transcend", "NCT05774756" ;
  schema:name "TRANSCEND"@en ;
  schema:alternateName "RM-493-040"@en, "RM-493 040"@en, "Trial 1"@en ;
  schema:description "This phase 3 trial showed that a daily injection which turns the brain's fullness signal back on cut body-mass index by about a sixth, and reduced hunger, in children and adults whose weight gain followed damage to the hypothalamus from a tumour or its treatment, while people on placebo gained weight; it supported the March 2026 US approval of Imcivree for that use."@en ;
  schema:url <https://onco.cc/trials/transcend/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05774756>, <https://doi.org/10.1056/NEJMoa2512275>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/craniopharyngioma/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:drugs <https://onco.cc/drugs/setmelanotide/> ;
  onco:companies <https://onco.cc/companies/rhythm-pharmaceuticals/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-transcend-miller-nejm-2026/> .